Overview

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Status:
Recruiting
Trial end date:
2023-07-06
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale [mFARS]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
PTC Therapeutics